Bill
HB 3406
Overview: HB 3406, "Relating to collecting a tax from all manufacturers and distributors of opioid drugs", is currently under consideration in the House Finance committee. The bill
Overview: HB 3406, "Relating to collecting a tax from all manufacturers and distributors of opioid drugs", is currently under consideration in the House Finance committee. The bill proposes to impose a tax on the manufacture and distribution of opioid drugs within the state.
Purpose and Intent: The primary goal of HB 3406 is to generate additional revenue that can be used to address the ongoing opioid crisis and its associated public health and social impacts. The tax is intended to hold opioid manufacturers and distributors accountable for their role in the crisis and provide funding for prevention, treatment, and recovery programs.
Key Provisions:
- Imposes a tax of $0.10 per milligram of active opioid ingredient on all manufacturers and distributors of opioid drugs
- Requires opioid manufacturers and distributors to register with the state and report their sales and distribution data
- Directs the revenue generated from the tax to a dedicated fund for opioid crisis response and mitigation efforts
Affected Parties and Impacts: The bill would directly impact opioid manufacturers and distributors, who would be required to pay the new tax and comply with the reporting requirements. The revenue generated from the tax would be used to support various programs and initiatives aimed at addressing the opioid crisis and its consequences for individuals, families, and communities.
Procedural and Timeline Considerations: HB 3406 was introduced on February 26, 2025, and is currently under consideration in the House Finance committee. The bill's progress and potential enactment into law will depend on the committee's review and the subsequent legislative process.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
